Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Sep 13, 2017 5:00pm
141 Views
Post# 26692329

RE:RE:GBM trial soon

RE:RE:GBM trial soonFrom Page 4 of the presentation, it would appear GBM is the next indication.  I would expect some form of money infusion soon to bring these trials along.  Hopefully HC can approve this next trial more timely than the NMIBC.

"Phase Ib clinical study has demonstrated high safety, tolerability and efficacy in the destruction of NMIBC and preclinically high safety, tolerability and efficacy in both NMIBC and Glioblastoma Multiforme (“GBM”) cancers"


Eoganacht wrote: The presentation had:

"New cancer indications Phase Ib clinical studies to commence in 4Q2017"

I wonder why it says "New cancer indications" rather than "GBM"? I wonder if there is a possibility of an additional or different indication trial starting in 4Q2017?


Ponching wrote:
I'm assuming patient 4 (first high dose) didn't have any issues for TLT to proceed with the GBM Phase 1 trial in Q4 2017 or Q1 2018 based from the new Corporate presentation.

TLT give us an update about the NMIBC trial!!! lol




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities